We are developing medical devices to treat cancer and infectious disease disorders. Our lineup of therapeutic candidates is among the most expansive in the field of extracorporeal blood purification. To optimize the benefit of drugs to treat cancer, we invented the ImmunePrepTM platform to enhance the performance of immunotherapeutic antibodies; ChemoPrepTM to improve the delivery of chemotherapy; and ChemoPureTM to reduce chemotherapy toxicity. Our lead therapeutic candidate is Sigyn TherapyTM to address infectious disease disorders that are not treatable with drugs. If successfully advanced, our therapies offer to provide strategic value to the pharmaceutical, dialysis, and organ transplant industry.
To learn more about our endeavors, we encourage you to navigate through our website. Additionally, you can click on the “Investors” button to access our SEC filings and register to receive email news alerts.
Our candidate solutions include: the ImmunePrep™ platform to enhance the activity of antibody-based immunotherapies, ChemoPrep™ to improve the delivery of cancer chemotherapies, ChemoPure™ to reduce the post-treatment toxicity of chemotherapy, and Sigyn Therapy™ to treat pathogen-associated inflammatory disorders that are not addressed with drug therapies.